



Robert Greene Sterne
 Edward J. Kessler
 Jorge A. Goldstein
 David K.S. Cornwell
 Robert W. Esmond
 Tracy-Gene G. Durkin
 Michele A. Cimbala
 Michael B. Ray
 Robert E. Sokohl
 Eric K. Steffe
 Michael Q. Lee
 Steven R. Ludwig
 John M. Covert
 Linda E. Alcorn
 Robert C. Millonig
 Lawrence B. Bugalsky
 Donald J. Featherstone
 Michael V. Messinger

Judith U. Kim
 Timothy J. Shea, Jr.
 Patrick E. Garrett
 Jeffrey T. Helvey*
 Heidi L. Kraus
 Crystal D. Sayles
 Edward W. Yee
 Albert L. Ferro*
 Donald R. Banowitz
 Peter A. Jackman
 Molly A. McCall
 Teresa U. Medler
 Jeffrey S. Weaver
 Kendrick P. Patterson
 Vincent L. Capuano
 Albert J. Fasulo II*
 Eldora Ellison Floyd
 W. Russell Swindell

Thomas C. Fiala
 Brian J. Del Buono
 Virgil Lee Beaston*
 Reginald D. Lucas*
 Kimberly N. Reddick
 Theodore A. Wood
 Elizabeth J. Haanes
 Bruce E. Chalker
 Joseph S. Ostroff
 Frank R. Cottingham*
 Christine M. Uhlier
 Rae Lynn Prengaman*
 Jane Shershenovich*
 Lawrence J. Carroll*
 George S. Bardmesser
 Rodney G. Maze

Registered Patent Agents*
 Karen R. Markowicz
 Andrea J. Kanage
 Nancy J. Leith
 Ann E. Summerfield
 Helene C. Carlson
 Gaby L. Longsworth
 Matthew J. Dowd
 Aaron L. Schwartz
 Angelique G. Uy
 Boris A. Matvenko
 Mary B. Tund
 Katrina Y. Pei
 Bryan L. Skelton
 Robert A. Schwartzman
 Jason D. Eisenberg
 John J. Figueroa

Senior Counsel
 Samuel L. Fox
 Kenneth C. Bass III
 Lisa A. Dunner

*Admitted only in Maryland
 *Admitted only in Virginia
 *Admitted only in Texas
 *Practice Limited to
 Federal Agencies

August 8, 2002

WRITER'S DIRECT NUMBER:

(202) 789-5525

INTERNET ADDRESS:

BRIAND@SKGF.COM

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

Art Unit 1636

Commissioner for Patents
 Washington, D.C. 20231

Re: U.S. Utility Patent Application
 Appl. No. 09/177,387; Filed: October 23, 1998
For: Recombinational Cloning Using Nucleic Acids Having Recombination
 Sites
 Inventors: Hartley *et al.*
 Our Ref: 0942.2850004/RWE/BJD

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Sixth Supplemental Information Disclosure Statement;
2. Three pages of Form PTO-1449 citing 21 documents;
3. A copy of each of the 21 cited documents; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
August 8, 2002
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

BJD/nef
Enclosures

::ODMA\MHODMA\SKGF_DC1;43401;1
SKGF Rev. 2/15/02 dcw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HARTLEY *et al.*

Appl. No.: 09/177,387

Filed: October 23, 1998

For: **Recombinational Cloning Using
Nucleic Acids Having
Recombination Sites**

Art Unit: 1636

Examiner: Yucel, I.

Atty. Docket: 0942.2850004/RWE/BJD

TECH CENTER 1600/2900

RECEIVED

AUG 09 2002

Sixth Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants in compliance with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of the documents is also included herewith.

The numbering on this Sixth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fifth Supplemental Information Disclosure Statement filed October 27, 2000, and in Applicants' Fourth Supplemental Information Disclosure Statement filed March 22, 2000, in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

This Sixth Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the Request for Continued Examination filed in the present matter on July 30, 2002. It is believed that no statement or fee is required. However, the U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: August 8, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600